证券研究报告 金融行业周报 ——信贷增速环比下滑，消费金融服务深化 证券分析师 王维逸S1060520040001（证券投资咨询） 袁喆奇S1060520080003（证券投资咨询） 李冰婷S1060520040002（证券投资咨询） 韦霁雯S1060524070004（证券投资咨询） 许 淼S1060525020001（证券投资咨询） 研究助理 李灵琇S1060124070021（一般证券业务） 请务必阅读正文后免责条款 2025年3月16日 1 核心观点 信贷增速环比下滑，消费金融服务深化 1、信贷增速环比下滑，社融增量保持平稳。3月14日，央行发布2月金融数据。1）新增人民币贷款：2025年2月新增人民币贷款增加10100亿元， 同比少增4400亿元，余额同比增速7.3%(Wind一致预期为7.4%)。分部门看，住户贷款少增3891亿元，其中，短期贷款少增2741亿元，中长期贷 款少增1150亿元;企(事)业单位贷款增加10400亿元，其中，短期贷款增加3300亿元，中长期贷款多增5400亿元，票据融资多增1693亿元。2）社 融规模：2025年2月社会融资规模增量为2.23万亿元(Wind一致预期为2 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company, indicating an expectation of stock performance that exceeds market performance by 10% to 20% over the next six months [1][8]. Core Insights - The company achieved a revenue of 17.17 billion yuan in 2024, representing a year-on-year growth of 9.9%, and a net profit of 840 million yuan, which is a 14.2% increase year-on-year. A cash dividend of 2.40 yuan per 10 shares is proposed [3][7]. - The report highlights improvements in gross margin and cost efficiency, with a gross margin of 12% in 2024, up 0.4 percentage points from the previous year. The management expense ratio decreased by 0.4 percentage points to 3.5% [7][8]. - The company has a strong presence in property management, managing 2,296 projects across 162 cities, with a total managed area of 365 million square meters [7][8]. Financial Summary - **Revenue and Profit Forecasts**: - 2024 Revenue: 17.17 billion yuan, 2025E: 18.46 billion yuan, 2026E: 19.81 billion yuan, 2027E: 21.15 billion yuan [6][9]. - 2024 Net Profit: 840 million yuan, 2025E: 914 million yuan, 2026E: 992 million yuan, 2027E: 1.068 billion yuan [6][9]. - **Profitability Ratios**: - Gross Margin: 12% in 2024, expected to remain stable at 12% in 2025 and 2026, with a slight increase to 12.1% in 2027 [10]. - Net Margin: 4.9% in 2024, projected to reach 5.0% in subsequent years [10]. - **Earnings Per Share (EPS)**: - EPS for 2024 is projected at 0.79 yuan, increasing to 0.86 yuan in 2025, 0.94 yuan in 2026, and 1.01 yuan in 2027 [10][11]. Market Position and Strategy - The company is positioned as a leading state-owned enterprise in property management, benefiting from strong resource endowments and market expansion advantages. It is expected to continue to thrive amid industry restructuring [8][9]. - The report notes a slight adjustment in EPS forecasts due to better-than-expected gross margin improvements, indicating a positive outlook for the company's financial performance [8].

Investment Rating - The report gives a "Buy" rating for Shanghai Pharmaceuticals (601607.SH) [1] Core Views - Shanghai Pharmaceuticals is positioned for growth with its industrial potential gradually being realized, driven by both innovative drugs and traditional Chinese medicine [7] - The company has a strong national presence in the pharmaceutical distribution sector, with over 2,000 quality brand pharmacies and more than 300 hospital supply chain service projects [7] - The CSO (Contract Sales Organization) business has shown significant growth, with sales reaching 2.9 billion yuan in 2023, a year-on-year increase of approximately 50% [7] - The company is expected to achieve net profits of 4.917 billion yuan, 5.608 billion yuan, and 6.283 billion yuan in 2024, 2025, and 2026 respectively [7] Summary by Sections 1. Company Overview - Shanghai Pharmaceuticals has a deep state-owned background and a comprehensive industrial chain layout, making it a leading player in the pharmaceutical sector [10] - The company has a strong focus on research and development, with a significant increase in R&D investment from 1.389 billion yuan in 2018 to 2.6 billion yuan in 2023 [29] 2. Pharmaceutical Industry - The innovative drug pipeline is extensive, with 60 projects in clinical research, including 46 innovative drugs [25][39] - Key products include I001, X842, and I037, which are expected to drive future growth [31][33][34] 3. Traditional Chinese Medicine - The company has eight major direct-controlled Chinese medicine enterprises and nine core Chinese medicine brands, with several recognized as top enterprises in the industry [40] - The acquisition of a 10% stake in Shanghai Huanhua Pharmaceutical is expected to enhance the company's market presence and internationalization efforts [7] 4. Financial Performance - The company achieved total revenue of 242.87 billion yuan in 2023, a year-on-year increase of 13.5%, with the pharmaceutical commercial sector contributing 93.31% of total revenue [18] - The gross profit margin for the pharmaceutical industrial sector was 58.5% in 2023, indicating strong profitability [18]

海外宏观 2025 年 3 月 16 日 宏观动态跟踪报告 美股调整之鉴：当下与 2024 年有何异同？ 证券分析师 | 钟正生 | 投资咨询资格编号 | | --- | --- | | | S1060520090001 | | | ZHONGZHENGSHENG934@pingan.com.cn | | 张璐 | 投资咨询资格编号 | | | S1060522100001 | | | ZHANGLU15@pingan.com.cn | | 范城恺 | 投资咨询资格编号 | | | S1060523010001 | | | FANCHENGKAI146@pingan.com.cn | 平安观点： 宏 观 动 态 跟 踪 券 研 究 报 告 报 告 证 共性：源于衰退担忧，叠加外部冲击。今年 2-3 月美股较快调整，而最近一 次类似调整在 2024 年 7-8 月。两次调整时间均达到或超过 14 个交易日， 标普 500 指数均下跌 8-10%左右，纳指调整幅度达 12-14%左右。两次美股 调整的背景有不少共性。第一，导火索都是经济数据引发的衰退担忧。2024 年 7 月，美国失业率上升触发"萨姆规则"，引燃 ...

公 司 报 告 房地产 2025年03月17日 招商积余(001914.SZ) 业绩稳增，质效并进 相关研究报告 【平安证券】招商积余（001914.SZ）*季报点评*业 绩稳健增长，规模再上台阶*推荐20241031 证券分析师 杨侃 投资咨询资格编号 S1060514080002 事项： 公司公布2024年年报，全年实现营业收入171.7亿元，同比增长9.9%，归母净 利润8.4亿元，同比增长14.2%，拟向全体股东每10股派发现金红利2.40元 （含税），不送红股，不以公积金转增股本。 平安观点： 推荐 ( 维持) 股价:10.84元 行情走势图 司 年 报 点 评 研 究 报 告 BQV514 YANGKAN034@pingan.com.cn 郑茜文 投资咨询资格编号 S1060520090003 ZHENGXIWEN239@pingan.com.cn | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 15,627 | 17,172 | 18,460 | 19, ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation of stock performance that exceeds market performance by 10% to 20% over the next six months [15]. Core Insights - The company achieved significant growth in 2024, with revenue reaching 17.907 billion yuan, a year-on-year increase of 32.39%, and a net profit of 1.878 billion yuan, up 34.29% year-on-year [4][5]. - The overall gross margin and net margin for 2024 were 24.83% (up 1.40 percentage points year-on-year) and 10.49% (up 0.16 percentage points year-on-year), respectively [5]. - The company is capitalizing on opportunities arising from the growth in AI technology, the demand for high-speed network communication, and the ongoing trends in automotive electrification and intelligence [5]. - The company is focusing on digitalization and smart manufacturing to enhance operational efficiency and reduce costs [5]. Financial Performance Summary - In 2024, the PCB business generated revenue of 10.494 billion yuan, a 29.99% increase year-on-year, accounting for 58.60% of total revenue, with a gross margin of 31.62% [5]. - The IC substrate business reported revenue of 3.171 billion yuan, a 37.49% increase year-on-year, representing 17.71% of total revenue, with a gross margin of 18.15% [5]. - The electronic assembly business achieved revenue of 2.823 billion yuan, a 33.20% increase year-on-year, contributing 15.76% to total revenue, with a gross margin of 14.40% [5]. - The company’s operating expenses showed effective cost control, with sales, management, R&D, and financial expense ratios remaining within 1 percentage point of the previous year [5]. Future Projections - Revenue is projected to grow to 22.205 billion yuan in 2025, with a year-on-year growth rate of 24.0% [7]. - Net profit is expected to reach 2.609 billion yuan in 2025, reflecting a year-on-year increase of 38.9% [7]. - The gross margin is anticipated to improve to 25.5% in 2025, while the net margin is expected to rise to 11.7% [7]. Market Position and Strategy - The company is recognized as a leading domestic IC substrate enterprise, benefiting from domestic substitution trends [11]. - The company is actively expanding its production capabilities, including projects in Thailand and Nantong, to support future business growth [11]. - The company is focusing on enhancing its product offerings in the automotive electronics sector, with orders growing over 50% for three consecutive years [9].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation of stock performance that exceeds market performance by 10% to 20% over the next six months [12]. Core Insights - The company achieved significant growth in 2024, with revenue reaching 17.907 billion yuan, a year-on-year increase of 32.39%, and a net profit of 1.878 billion yuan, up 34.29% year-on-year [4][5]. - The overall gross margin and net margin for 2024 were 24.83% (up 1.40 percentage points YoY) and 10.49% (up 0.16 percentage points YoY), respectively [5]. - The company is capitalizing on opportunities arising from the growth in AI technology, electric vehicle trends, and the recovery of the general server market [5]. - The company is focusing on digitalization and smart manufacturing to enhance competitiveness and control costs [5]. Financial Performance Summary - **Revenue Breakdown**: - PCB business: Revenue of 10.494 billion yuan, up 29.99% YoY, accounting for 58.60% of total revenue with a gross margin of 31.62% [5]. - IC substrate business: Revenue of 3.171 billion yuan, up 37.49% YoY, accounting for 17.71% of total revenue with a gross margin of 18.15% [5]. - Electronic assembly business: Revenue of 2.823 billion yuan, up 33.20% YoY, accounting for 15.76% of total revenue with a gross margin of 14.40% [5]. - **Cost Control**: The company maintained stable expense ratios across sales, management, R&D, and financial expenses, all within a 1 percentage point change [5]. - **Future Projections**: The company expects continued revenue growth, with projected revenues of 22.205 billion yuan in 2025, 27.534 billion yuan in 2026, and 34.143 billion yuan in 2027, reflecting a compound annual growth rate of 24% [6][10]. Financial Ratios - **Profitability**: The projected gross margin is expected to improve to 25.5% in 2025 and 26.0% in 2026, with net margin reaching 11.7% and 12.5% respectively [10]. - **Return on Equity (ROE)**: Expected to increase from 12.8% in 2024 to 15.7% in 2025 and further to 18.8% by 2027 [10]. - **Valuation Metrics**: The price-to-earnings (P/E) ratio is projected to decrease from 37.9 in 2024 to 27.3 in 2025, indicating improving valuation as earnings grow [10].

证券研究报告 人形机器人系列专题（二） 执行系统之旋转关节：扭矩跃升，动力内核 电子行业 强于大市（维持） 证券分析师 徐碧云 投资咨询资格编号：S1060523070002 2025年3月17日 请务必阅读正文后免责条款 投资要点 风险提示：1）人工智能技术发展不及预期。2）行业竞争加剧风险。3）技术迭代不及预期。 1 执行器：驱动关节活动，电驱动已成主导。执行器即一体化关节，其本质是将电机的旋转运动转化为驱动连杆机构的运动。执行器当前占人形机器 人整体成本约55%，性能和成本主要取决于核心零部件。根据动力来源，执行器可分为液压、气动和电驱动三类，电驱动凭借成本低、控制精度高和 密闭性优等特点，成为主流方案。人形机器人躯干的执行器分为旋转执行器与线性执行器两类，不同之处在于传动机构：旋转执行器采用减速器， 而线性执行器采用行星滚柱丝杠，国内大部分本体厂以旋转执行器方案为主。从趋势上看，高性能、智能化、微型化的一体化关节模组是降低人形 机器人制造成本的关键。 电机：产生驱动转矩，无框力矩电机应用广泛。电机是将电能转换为机械能的动力源，是人形机器人中最常用的驱动器件之一。机器人自由度越高， 所需的电机数量越多。 ...

海外宏观 2025 年 3 月 17 日 海外宏观周报 美国通胀降温，关税威胁延续 证券分析师 | 钟正生 | 投资咨询资格编号 | | --- | --- | | | S1060520090001 | | | ZHONGZHENGSHENG934@pingan.com.cn | | 张璐 | 投资咨询资格编号 | | | S1060522100001 | | | ZHANGLU150@pingan.com.cn | | 范城恺 | 投资咨询资格编号 | | | S1060523010001 | | | FANCHENGKAI146@pingan.com.cn | 平安观点： 观 报 告 宏 观 周 报 证 券 研 究 报 告 请通过合法途径获取本公司研究报告，如经由未经许可的渠道获得研究报告，请慎重使用并注意阅读研究报告尾页的声明内容。 宏 海外经济政策。1）美国：政策方面，美国对钢铁和铝加征 25%关税于 3 月 12 日正式生效，本周曾威胁对加拿大钢铝加征额外 25%关税；特朗普威胁 将对欧盟葡萄酒征收 200%关税。特朗普团队倾向推荐鲍曼任美联储监管副 主席。美国参议院投票通过支出法案，避免政府停摆。 ...

海外宏观 2025 年 3 月 17 日 海外宏观周报 美国通胀降温，关税威胁延续 证券分析师 | 钟正生 | 投资咨询资格编号 | | --- | --- | | | S1060520090001 | | | ZHONGZHENGSHENG934@pingan.com.cn | | 张璐 | 投资咨询资格编号 | | | S1060522100001 | | | ZHANGLU150@pingan.com.cn | | 范城恺 | 投资咨询资格编号 | | | S1060523010001 | 平安观点： 宏 观 报 告 宏 观 周 报 证 券 研 究 报 告 FANCHENGKAI146@pingan.com.cn 海外经济政策。1）美国：政策方面，美国对钢铁和铝加征 25%关税于 3 月 12 日正式生效，本周曾威胁对加拿大钢铝加征额外 25%关税；特朗普威胁 将对欧盟葡萄酒征收 200%关税。特朗普团队倾向推荐鲍曼任美联储监管副 主席。美国参议院投票通过支出法案，避免政府停摆。经济数据方面，美国 2 月 CPI 和核心 CPI 环比均录得 0.2%、均低于预期。美国 2 月 PPI 同比上 涨 3.2 ...